Provided by Tiger Trade Technology Pte. Ltd.

Arvinas Holding Company LLC

9.37
+0.34003.77%
Post-market: 9.370.00000.00%19:30 EDT
Volume:951.75K
Turnover:8.84M
Market Cap:612.34M
PE:70.06
High:9.39
Open:9.02
Low:9.00
Close:9.03
52wk High:14.51
52wk Low:6.97
Shares:65.39M
Float Shares:56.67M
Volume Ratio:1.77
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1337
EPS(LYR):-1.1400
ROE:1.59%
ROA:-1.01%
PB:1.09
PE(LYR):-8.21

Loading ...

Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU

Reuters
·
Jun 18

Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment

TIPRANKS
·
Jun 17

BRIEF-Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026

Reuters
·
Jun 17

Arvinas - Pfizer, and Rigel Receive Hsr Clearance for License Agreement on June 11, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 17

Arvinas - Co and Pfizer Eligible for up to $320 Mln in Milestone Payments and Tiered Royalties - SEC Filing

THOMSON REUTERS
·
Jun 17

Rigel closes VEPPANU license deal, makes USD 70 million upfront payment

Reuters
·
Jun 17

Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s

Reuters
·
Jun 04

Arvinas Joins the Michael J. Fox Foundation’s Lite and Ppmi Programs to Advance New Therapies Targeting Lrrk2 for Parkinson’s Disease

THOMSON REUTERS
·
Jun 04

Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.

Dow Jones
·
Jun 03

Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)

TIPRANKS
·
Jun 03

Arvinas Holding Company (ARVN) Gets a Buy from Barclays

TIPRANKS
·
Jun 03

Arvinas - Expects Cash Position as of March 31, 2026 to Fund Operations Into Second Half of 2028 - SEC Filing

THOMSON REUTERS
·
Jun 03

Arvinas - Plans to Seek Out-Licensing Agreement for Additional Clinical Trials of Arv-806 - SEC Filing

THOMSON REUTERS
·
Jun 03

Arvinas - Announces Re-Prioritization of Portfolio Following Strategic Review - SEC Filing

THOMSON REUTERS
·
Jun 03

Arvinas - Plans to Complete Phase 1 Monotherapy Dose Escalation Trial and Share Data in 2026 - SEC Filing

THOMSON REUTERS
·
Jun 03

Arvinas to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 30

Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Beta Bionics, Inc. (BBNX) and Arvinas Holding Company (ARVN)

TIPRANKS
·
May 22

Wells Fargo Remains a Buy on Arvinas Holding Company (ARVN)

TIPRANKS
·
May 22

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN)

TIPRANKS
·
May 22

Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN) and SCHOTT Pharma AG & Co. KGaA (Milan: IT:1SXP)

TIPRANKS
·
May 16